QuantX Biosciences
PVT · PVT·Princeton, NJ·Private·Preclinical
Privately held drug discovery company developing oral small-molecule therapeutics for immunology and inflammation. Combines physics-based and statistical computational modeling to design candidates against clinically validated targets. Lead programs are oral small molecule inhibitors of STAT6 (atopic dermatitis) and IL-17 (psoriasis), both in IND-enabling studies. Founded 2022 by Wayne Tang and Yax Sun; closed an oversubscribed $85M Series B in 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| QuantX Biosciences website | Website | May 3, 2026 | 4 |